The University of Chicago Header Logo

Connection

Rudolph Navari to Aged

Back to Details
This is a "connection" page, showing publications Rudolph Navari has written about Aged.
Rudolph Navari
Connection Strength
0.654
Aged
  1. Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin. Oncologist. 2021 04; 26(4):325-331.
    View in: PubMed
    Score: 0.055
  2. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol. 2020 06 01; 6(6):895-899.
    View in: PubMed
    Score: 0.053
  3. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
    View in: PubMed
    Score: 0.051
  4. Safety of Polysorbate 80 in the Oncology Setting. Adv Ther. 2018 Jun; 35(6):754-767.
    View in: PubMed
    Score: 0.046
  5. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):134-42.
    View in: PubMed
    Score: 0.040
  6. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015 Sep; 16(9):1079-1089.
    View in: PubMed
    Score: 0.038
  7. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jun; 21(6):1655-63.
    View in: PubMed
    Score: 0.032
  8. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011 Sep-Oct; 9(5):188-95.
    View in: PubMed
    Score: 0.029
  9. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010 Aug; 18(8):951-6.
    View in: PubMed
    Score: 0.025
  10. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201.
    View in: PubMed
    Score: 0.022
  11. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007 Nov; 15(11):1285.
    View in: PubMed
    Score: 0.021
  12. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2005 Aug; 30(2):175-82.
    View in: PubMed
    Score: 0.019
  13. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer. 2005 Jul; 13(7):529-34.
    View in: PubMed
    Score: 0.018
  14. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2004 Oct; 4(5):715-24.
    View in: PubMed
    Score: 0.018
  15. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage. 2003 May; 25(5):438-43.
    View in: PubMed
    Score: 0.016
  16. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021 Jul; 29(7):3439-3459.
    View in: PubMed
    Score: 0.014
  17. Preferences of patients with advanced cancer for hospice care. JAMA. 2000 Nov 15; 284(19):2449.
    View in: PubMed
    Score: 0.014
  18. Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE). J Geriatr Oncol. 2020 03; 11(2):270-273.
    View in: PubMed
    Score: 0.012
  19. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
    View in: PubMed
    Score: 0.012
  20. Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22.
    View in: PubMed
    Score: 0.012
  21. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92.
    View in: PubMed
    Score: 0.010
  22. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
    View in: PubMed
    Score: 0.010
  23. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995 Sep; 13(9):2408-16.
    View in: PubMed
    Score: 0.009
  24. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015 Sep; 16(9):1071-1078.
    View in: PubMed
    Score: 0.009
  25. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
    View in: PubMed
    Score: 0.009
  26. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct; 12(10):2204-10.
    View in: PubMed
    Score: 0.009
  27. Comparison of intermittent ondansetron versus continuous infusion metoclopramide used with standard combination antiemetics in control of acute nausea induced by cisplatin chemotherapy. Cancer. 1993 Jul 15; 72(2):583-6.
    View in: PubMed
    Score: 0.008
  28. Hypothermia. Ala J Med Sci. 1984 Oct; 21(4):374-81.
    View in: PubMed
    Score: 0.004
  29. A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
    View in: PubMed
    Score: 0.004
  30. The peripheral blood smear in heat stroke. An aid to diagnosis. Ala J Med Sci. 1983 Apr; 20(2):137-40.
    View in: PubMed
    Score: 0.004
  31. Bone marrow necrosis in acute leukemia. Acta Haematol. 1983; 69(3):158-63.
    View in: PubMed
    Score: 0.004
  32. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.
    View in: PubMed
    Score: 0.004
  33. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36.
    View in: PubMed
    Score: 0.004
  34. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
    View in: PubMed
    Score: 0.003
  35. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
    View in: PubMed
    Score: 0.003
  36. Oral ondansetron 8 mg twice daily is as effective as 8 mg three times daily in the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. S3A-376 Study Group. Cancer Invest. 1997; 15(4):297-303.
    View in: PubMed
    Score: 0.003
  37. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Cancer. 1996 Aug 15; 78(4):789-93.
    View in: PubMed
    Score: 0.003
  38. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
    View in: PubMed
    Score: 0.003
  39. Protein turnover in advanced lung cancer patients. Metabolism. 1993 Mar; 42(3):291-6.
    View in: PubMed
    Score: 0.002
  40. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992 Dec; 10(12):1969-75.
    View in: PubMed
    Score: 0.002
  41. Glucose metabolism in advanced lung cancer patients. Nutrition. 1992 Jul-Aug; 8(4):245-51.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.